Acute Seizure Management in Adults

First‑Line Therapy – Benzodiazepines

Immediate administration of a benzodiazepine (lorazepam, diazepam, or midazolam) is recommended for generalized convulsive seizures lasting ≥5 minutes or for multiple seizures without return to baseline. Level A evidence supports this approach. 1

Second‑Line Therapy (after benzodiazepine failure)

Valproate (preferred)

Give 30 mg/kg IV infused at 6 mg/kg/min (maximum 40 mg/min). 1
Achieves seizure termination in ≈ 88 % of patients within 20 minutes. 2
Does not cause hypotension (phenytoin causes hypotension in ~12 % of cases). 2
Common adverse effects include dizziness, thrombocytopenia, hepatic toxicity, and hyperammonemia. 1
Contraindicated in pregnancy, known liver disease, and mitochondrial disorders. 2

Levetiracetam (preferred)

Give 30–50 mg/kg IV infused at 5 mg/kg/min (maximum 2.5–3 g). 1
Results in seizure cessation in 68–73 % of patients. 3
Adverse effects are uncommon and include nausea and rash. 1
Particularly useful in patients with cardiovascular instability or polypharmacy. 2

Fosphenytoin (alternative)

Give 18–20 mg/kg phenytoin‑equivalents IV at 50 mg/min. 1
Terminates seizures in only 50–56 % of cases. 2
Associated adverse events: hypotension (~12 %), cardiac dysrhythmias, soft‑tissue injury with extravasation, and purple‑glove syndrome. [1][2]
Reserve for use only when valproate and levetiracetam are contraindicated or unavailable. 4

Evidence Summary

The 2024 ESETT trial (Class I) demonstrated comparable overall seizure‑cessation rates (~50 %) for valproate, levetiracetam, and fosphenytoin, but valproate and levetiracetam had significantly better safety profiles (lower hypotension and intubation rates). 4

Third‑Line Therapy – Refractory Status Epilepticus

Initiate continuous intravenous anesthetic infusion with simultaneous continuous EEG monitoring. 1

Propofol (preferred for safety)

Administer 2 mg/kg IV bolus, then infuse at 3–7 mg/kg/h. 1

Midazolam (alternative anesthetic)

Administer 0.2 mg/kg IV bolus, then infuse at 0.1–2 mg/kg/h. 1

Continuous EEG is mandatory to titrate therapy to burst suppression or seizure cessation and to detect breakthrough seizures. 5

Long‑Term Antiseizure Medication Selection

Levetiracetam, valproate, lamotrigine, and carbamazepine are appropriate first‑line agents for chronic management, chosen according to seizure type, patient age, comorbidities, and drug‑interaction profile. 5

Phenytoin should be avoided for long‑term therapy because of its unfavorable side‑effect and interaction profile. 2

Identification and Treatment of Reversible Causes

Promptly assess and correct drug toxicity or withdrawal (e.g., alcohol, benzodiazepines, barbiturates) and hypertensive emergencies as part of seizure management. 1

EEG Monitoring Indications

Continuous EEG is indicated for all patients with refractory status epilepticus requiring anesthetic therapy. 2

Common Pitfalls to Avoid

Do not select phenytoin as the first‑line second‑line agent when valproate or levetiracetam are available; they have superior safety. 4
Do not delay administration of second‑line therapy while awaiting benzodiazepine effect; give promptly if seizures persist. 4

Evidence‑Based Recommendations for Acute Seizure Abortion

First‑Line Benzodiazepine Therapy

• Administer a benzodiazepine immediately to any patient with a seizure lasting ≥ 5 minutes or with multiple seizures without return to baseline to halt status epilepticus. 6

Second‑Line Antiseizure Medications (after adequate benzodiazepine dose)

Valproate (preferred)

• Dose: 30 mg/kg IV infused at 6 mg/kg /min (maximum 40 mg/min). 7
• Efficacy: Terminates seizures in ≈ 88 % of patients within 20 minutes. 7
• Safety advantage: Does not cause hypotension, whereas phenytoin induces hypotension in ≈ 12 % of cases. 7
• Administration speed: Can be given more rapidly than phenytoin with fewer adverse effects. 7
• Common adverse effects: Dizziness, thrombocytopenia, hepatic toxicity, hyperammonemia. 7

Levetiracetam (preferred)

• Dose: 30–50 mg/kg IV infused at 5 mg/kg /min (maximum 2.5–3 g). 7
• Efficacy: Achieves seizure cessation in 68–73 % of patients. 8
• Safety profile: Minimal adverse effects (occasional nausea or rash); no clinically significant hypotension or respiratory depression. 8

Comparative Trial Evidence (ESETT, 2024)

• In a multicenter randomized trial, levetiracetam, fosphenytoin, and valproate produced similar overall seizure‑cessation rates at 60 minutes (≈ 45–47 %). 6
• Valproate and levetiracetam demonstrated significantly superior safety, with lower rates of hypotension and need for intubation compared with fosphenytoin. 6

Alternative Second‑Line Agent (when valproate and levetiracetam are contraindicated)

Fosphenytoin (or phenytoin)

• Dose: 18–20 mg phenytoin equivalents/kg IV at ≤ 150 mg PE/min. 7
• Efficacy: Terminates seizures in only 50–56 % of cases, markedly lower than valproate or levetiracetam. 7
• Adverse effects: Hypotension (~12 %), cardiac dysrhythmias, soft‑tissue injury with extravasation, and “purple glove” syndrome. 7
• Tolerability: Fosphenytoin is preferred over phenytoin (Level A evidence). 7

Third‑Line Anesthetic Management (refractory status epilepticus)

Propofol (preferred for safety)

• Dose: 2 mg/kg IV bolus (repeat in 3–5 min if needed); maintenance infusion 3–7 mg/kg/h. 7
• Ventilation duration: Reduces mechanical ventilation time to ≈ 4 days versus ≈ 14 days with pentobarbital. 7
• Hypotension risk: Occurs in 42 % of patients, compared with 77 % with barbiturates. 7

Pentobarbital (alternative, higher efficacy, higher risk)

• Dose: 13 mg/kg IV bolus followed by 2–3 mg/kg/h infusion. 7
• Efficacy: Achieves seizure control in 92 % of patients versus 73 % with propofol. 7
• Risks: Higher rates of severe hypotension and prolonged respiratory depression. 7

Phenobarbital (additional option)

• Dose: 10–20 mg/kg IV; may repeat 5–10 mg/kg after 10 minutes. 7
• Efficacy: Effective in 58 % of cases when used as the initial medication. 7
• Risks: Notable potential for respiratory depression and hypotension. 7

All recommendations are based on the cited peer‑reviewed evidence and reflect the highest‑quality data available (e.g., multicenter randomized trials, Level A evidence where specified).

First‑Line Management of Myoclonic Seizures

Primary Pharmacotherapy

• Valproate is the primary first‑line medication for myoclonic seizures, with levetiracetam and benzodiazepines (particularly clonazepam) serving as equally effective alternatives or adjunctive agents. 9

Acute Myoclonic Status Epilepticus

• First‑line: Intravenous benzodiazepine—lorazepam 0.1 mg/kg IV (maximum 4 mg) or midazolam 0.2 mg/kg intramuscularly (maximum 10 mg). 9
• Second‑line: Intravenous valproate 30 mg/kg or intravenous levetiracetam 30–50 mg/kg. 9

Guideline Recommendation for Status Epilepticus

• Benzodiazepines are specifically indicated for status epilepticus with myoclonic seizures that occur without perceptible disturbances of consciousness in idiopathic generalized epilepsy. 9